- Conditions
- Glycogen Storage Disease Type II
- Interventions
- avalglucosidase alfa
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 0 Days to 12 Months
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 6
- States / cities
- Stanford, California • Minneapolis, Minnesota • Hawthorne, New York + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pompe Disease, Pregnancy
- Interventions
- avalglucosidase alfa-NGPT (GZ402666) IV, avalglucosidase alfa-NGPT (GZ402666)
- Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Glycogen Storage Disease Type II;Pompe's Disease
- Interventions
- Avalglucosidase alfa (GZ402666), Alglucosidase alfa (GZ419829)
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 3 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Los Angeles, California • Orange, California + 18 more
- Conditions
- Pompe Disease, Glycogen Storage Disease Type II (GSD II), Acid Maltase Deficiency
- Interventions
- GZ402666
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Kansas City, Kansas + 4 more
- Conditions
- Glycogen Storage Disease Type II-Pompe's Disease
- Interventions
- Avalglucosidase alfa (GZ402666), Alglucosidase alfa (GZ419829)
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2027
- U.S. locations
- 3
- States / cities
- Valhalla, New York • Durham, North Carolina • Seattle, Washington
- Conditions
- Glycogen Storage Disease Type II Pompe Disease
- Interventions
- Avalglucosidase Alfa
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- Not listed
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Kansas City, Kansas + 5 more